Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.38 |
| ▸ | FEN1 | P39748 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16617423 | 0.89 | FEN1 (0.42) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL18622659 | 0.81 | FEN1 (0.41) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL16618084 | 0.81 | FEN1 (0.44) | ALOX5APFEN1HTTGAA | |
| SCHEMBL16624992 | 0.80 | ALOX5AP (0.38) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL16624984 | 0.79 | FEN1 (0.40) | ALOX5APFEN1HTTGAA | |
| SCHEMBL16617075 | 0.76 | ALOX5AP (0.39) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL16624994 | 0.73 | KDM4E (0.34) | ALOX5APFEN1 | |
| SCHEMBL5123913 | 0.71 | HTT (0.38) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL29665819 | 0.71 | SRC (0.40) | ALOX5APFEN1HTTGAAALDH1A1 | |
| SCHEMBL2259532 | 0.71 | GRM5 (0.43) | HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2017-03-16 | — | — | US | disclosed |
| US-9533959-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-01-03 | — | — | US | disclosed |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2016-06-09 | — | — | US | disclosed |
| US-9296727-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | VERTEX PHARMACEUTICALS (EUROPE) LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073315-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | ALOX5AP 2322/4885FEN1 305/4885HTT 2870/4885 |
| US-20160159749-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | ALOX5AP 2322/4885FEN1 305/4885HTT 2870/4885 |
| US-10005737-B2 | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines | TYMS, UMPS, DPYD | ALOX5AP 2322/4885FEN1 305/4885HTT 2870/4885 |
| US-20150099875-A1 | METHODS OF REGIOSELECTIVE SYNTHESIS OF 2,4-DISUBSTITUTED PYRIMIDINES | TYMS, UMPS, DPYD | ALOX5AP 2322/4885FEN1 305/4885HTT 2870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.